People. Processes. Performance. Strategies for Clinical Studies & Human Factors Research Ginger Clasby, MS EVP, Business Development Promedica International.

Slides:



Advertisements
Similar presentations
Elizabeth Mansfield, PhD OIVD Public meeting July 19, 2010
Advertisements

Integrating the NASP Practice Model Into Presentations: Resource Slides Referencing the NASP Practice Model in professional development presentations helps.
Adverse Event Reporting: Getting started Lynn Bahta, R.N., B.S.N Minnesota Department of Health August 2008.
An Outline for: A User-Based Systems Approach to the Evaluation, Selection, and Institutionalization of Safer Medical Devices.
ELTSS Alignment to Nationwide Interoperability Roadmap DRAFT: For Stakeholder Consideration in response to public comment.
Building the capacity of Community Health Centers to collect occupational health data Letitia Davis, ScD, EdM Occupational Health Surveillance Program.
© Safeguarding public health Adverse incident reporting now and the future, roles and responsibilities Mark Grumbridge.
Strengthening the Medical Device Clinical Trial Enterprise
POC INR Testing Rural and Remote Session 2015 CADTH SYMPOSIUM Janice Mann MD Knowledge Mobilization, CADTH.
Clinical Trials Medical Interventions
Capturing and Reporting Adverse Events in Clinical Research
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Introduction and Overview “the grid” – a proposed distributed computing infrastructure for advanced science and engineering. Purpose: grid concept is motivated.
Journal Club Alcohol and Health: Current Evidence July–August 2005.
What Do Toxicologists Do?
Brookhaven Science Associates U.S. Department of Energy 1 Brookhaven National Laboratory Protocol Compliance Monitoring Darcy Mallon May 7, 2009.
CDRH Software Regulation
William B Munier, MD, MBA, Director Center for Quality Improvement and Patient Safety Agency for Healthcare Research and Quality AHRQ Annual Conference.
Radiological Devices Advisory Committee Meeting November 18, 2009 John A. DeLucia iCAD, Inc.
GLOBAL REGULATORY STRATEGY CONSIDERATIONS SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES SEPTEMBER 14-17, 2008 BOSTON, MA.
The IRB's Position on Quality Projects vs. Research R. Peter Iafrate, Pharm.D. Chairman, Health Center IRB University of Florida.
Joy Hamerman Matsumoto.  St Jude Medical Cardiac Rhythm Management Division manufactures implantable cardiac devices ◦ Pacemakers ◦ Implanted defibrillators.
QUALITY MANAGEMENT SYSTEM ACCORDING TO ISO
Who’s the Boss? Faculty Advisor or Principal Investigator Supervision versus Student Investigator or Study Coordinator Responsibilities Gwenn Snow, MS,
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
Yesterday, today, and tomorrow
Presenter-Dr. L.Karthiyayini Moderator- Dr. Abhishek Raut
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
MassMEDIC Risk Management: Legal and Liability Issues with Home Healthcare Products Raymond C. Zemlin Goodwin Procter LLP (March 9, 2006) ©2006. Goodwin.
Approach and Key Components. The Goal of Cities for Life: To help community groups and primary care providers create an environment that facilitates and.
FDA Approach to Review of Outcome Measures for Drug Approval and Labeling: Content Validity Initiative on Methods, Measurement, and Pain Assessment in.
1. Infection Control Risk Assessment Terrie B. Lee, RN, MS, MPH, CIC Director, Infection Prevention & Employee Health Charleston Area Medical Center Charleston,
Institutional Review Board (IRB) for Human Subject Protections: Working with the IRB Erin McClure, PhD Department of Psychiatry and Behavioral Sciences.
Preventing Surgical Complications Prevent Harm from High Alert Medication- Anticoagulants in Primary Care Insert Date here Presenter:
MODULE B: Case Report Forms Jane Fendl & Denise Thwing April 7, Version: Final 07-Apr-2010.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Laura M. Lee, R.N. Clinical Center, NIH The Epidemiology of Clinical Errors in a Research Hospital: Mining Occurrence Reporting Data for Mining Occurrence.
Chapter 6 CRISIS MANAGEMENT. Introduction - Crisis: ◦is a situation that specifically involves a pharmaceutical product, medical device or activity with.
TERRENCE F. ACKERMAN, PH.D. PROFESSOR OF BIOETHICS CHAIR, UTHSC IRB.
Building Clinical Infrastructure and Expert Support Michael Steinberg, MD, FACR ULAAC Disparity Project Centinela/Freeman Health System.
Module 3. Session Clinical Audit Prepared by J Moorman.
The NCI Central IRB Initiative Third Annual Medical Research Summit Washington, D.C. March 2003.
Management of Change ► The health, safety, security, environmental, technical and other impacts of temporary and permanent changes are formally assessed,
Data, Security and Human Subjects Research Deborah Barnard, MS.
Guidance Training CFR §483.75(i) F501 Medical Director.
Joel Gerber Zachary Reaver Kurt Schilling.  Provides physical proof of development  Maintains product design knowledge base  Meets government and corporate.
Understanding Clinical Trials – Part 2 Georgianne Arnold, MD Professor of Pediatrics University of Pittsburgh Medical Center Pittsburgh Children’s Hospital.
Learning Outcomes Discuss current trends and issues in health care and nursing. Describe the essential elements of quality and safety in nursing and their.
Experiences at JHS and the Ryder Trauma Center Joseph Sharit University of Miami Department of Industrial Engineering.
Regulatory Guidance for Genetic Testing. Three Specific Areas Laboratory tests Results of genetic testing – Clinical – Research GenomeWide Association.
Applying New Science to Drug Safety Janet Woodcock, M.D. Acting Deputy Commissioner for Operations April 15, 2005.
Levels of Review of Research and Quality Improvement Walter Kraft, MD Associate Director, Office of Human Subjects Protection Department of Pharmacology.
ACGME SIX CORE COMPETENCIES Minimum Program Requirements Language Approved by the ACGME, September 28, 1999 “The residency program must require its residents.
Methodological Issues in Implantable Medical Device(IMDs) Studies Abdallah ABOUIHIA Senior Statistician, Medtronic.
Mobile Technology Improves Patient Outcomes JULIE POPE COLUMBUS STATE UNIVERSITY.
Background Methods Results Discussion Conclusion
Is a Clinical Trial Right for Me?
Susan Sonne, PharmD, BCPP Chair, MUSC IRB II
Russell Glasgow Marina McCreight Borsika Rabin
FDA’s IDE Decisions and Communications
An Integrated Risk Management & Safety Program: IRMSP
MUHC Innovation Model.
Clinical Trials Medical Interventions
Bozeman Health Clinical Research
Erica Takai, PhD for Andrew Farb, M.D.
Crucial Statistical Caveats for Percutaneous Valve Trials
Clinical Trials.
Is a Clinical Trial Right for Me?
Tobey Clark, Director*, Burlington USA
Regulatory Perspective of the Use of EHRs in RCTs
Presentation transcript:

People. Processes. Performance. Strategies for Clinical Studies & Human Factors Research Ginger Clasby, MS EVP, Business Development Promedica International

Product Development Priorities Minimize Medical Device Hazards Understand user requirements Design/engineer for consistent performance Minimize likelihood of user-related errors

Importance of HFE Why Products Don’t Sell Not easy to use Significant service requirements Price disproportionate to benefit Difficult to manufacture

Field Test Case Study Cordguard™ Umbilical Cord Management System Used in delivery room Used in delivery room Unified system for umbilical cord clamping, cutting and blood collection Unified system for umbilical cord clamping, cutting and blood collection Collects neonatal blood samples while minimizing chance of clinician exposure to blood Collects neonatal blood samples while minimizing chance of clinician exposure to blood

Clinical Studies What Do You Want to Accomplish? Device failure modes and rates User error types and rates Device efficacy Cost – benefit analysis Comparison vs. “gold standard”

Clinical Studies What Did We Want to Accomplish? Determine device failure modes & rates Determine user error types & rates Gather subjective feedback regarding device use Target sample – 100 births

Who Are Product Users? Considerations. General health and mental state Physical size and strength Sensory capabilities Coordination Cognitive ability and memory Knowledge about device operation/associated medical condition Previous experience with similar devices/expectations about device operation Motivation and ability to adapt to adversity

Who Were Cordguard™ Users? Considerations. Midwives (low-risk deliveries) Residents (teaching hospitals) Obstetricians Neonatologists (high-risk deliveries) Labs Fathers/family members (may know nothing)

What Do We Want to Accomplish? Considerations. Written protocol Study objective(s) User population Methodology Data capture Product development team and clinician review

Where to Evaluate? Considerations. Convenience Cost Regulatory considerations Medical center requirements

Where Was Cordguard™ Evaluated? Considerations. Hospitals with large birthing population Appropriate “mix” of users Physician-supporters on-staff

When & How to Implement? Considerations. Patient consent Institutional Review Board approval Patient availability User training Data capture

When & How to Implement? Cordguard™ Considerations. Randomly occurring patient availability 24/7 In-service required for a large, frequently changing user pool Presence required at time of use Data collection done by company personnel

Evaluating Study Results Objective and Subjective Data. Compare results to investigational plan success parameters Utilize clinician advisors for interpretation Assess needs for additional design modifications and impact on total program

Evaluating Cordguard™ Study Results Objective and Subjective Data. Failure rate too high Cumbersome design Unacceptable design limitations re: blood collection Cost concerns Philosophical objections from users

Evaluating Cordguard™ Study Results Next Steps. Initial product premise was flawed Significant engineering work remained Product development activities cancelled

Human Factors Engineering Guidance References. Do It by Design: An Introduction to Human Factors, FDA Office of Communication, Education & Radiation Programs Do It by Design: An Introduction to Human Factors, FDA Office of Communication, Education & Radiation Programs Guidance for Industry & FDA Premarket and Design Control Reviewers – Medical Device Use-Safety: Incorporating Human Factors Engineering into Risk Management, 7/18/2000 Guidance for Industry & FDA Premarket and Design Control Reviewers – Medical Device Use-Safety: Incorporating Human Factors Engineering into Risk Management, 7/18/2000 Human Factors Design Process for Medical Devices: ANSI/AAMI HE74:2001 Human Factors Design Process for Medical Devices: ANSI/AAMI HE74:2001